The Technical Analyst
Immuneering Corporation [IMRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Immuneering Corporation Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.55% $1.480
America/New_York / 26 apr 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 43.34 mill |
| EPS: | -1.880 |
| P/E: | -0.790 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 29.28 mill |
| Avg Daily Volume: | 0.715 mill |
| RATING 2024-04-26 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.790 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.13x |
| Company: PE -0.790 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.933 (30.64%) $0.453 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.016 - 1.924 ( +/- 30.88%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Cormorant Asset Management, Lp | Sell | 100 | Class A Common Stock |
| 2024-04-01 | Cormorant Asset Management, Lp | Sell | 300 | Class A Common Stock |
| 2024-04-01 | Cormorant Asset Management, Lp | Sell | 100 | Class A Common Stock |
| 2024-04-01 | Cormorant Asset Management, Lp | Sell | 600 | Class A Common Stock |
| 2024-04-01 | Cormorant Asset Management, Lp | Sell | 10 | Class A Common Stock |
| INSIDER POWER |
|---|
| 6.71 |
| Last 92 transactions |
| Buy: 3 241 516 | Sell: 1 367 921 |
Forecast:
16:00 - $1.470
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.470
Forecast 2: 16:00 - $1.470
Forecast 3: 16:00 - $1.470
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.480 (3.55% ) |
| Volume | 0.269 mill |
| Avg. Vol. | 0.715 mill |
| % of Avg. Vol | 37.71 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IMRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IMRX
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Latest Press Releases
2024-04-09 12:00:00 - Press Release
Imm-1-104 Is Synergistic With Chemotherapy In Pancreatic Cancer Models
- preclinical data presented at aacr demonstrate that combining imm-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone - - patients are now on treatment in multiple arms of the ongoing phase 2a trial, including multiple patients with pancreatic cancer who are being treated with imm-1-104 in combination with chemotherapy in the first-line setting - - immuneering expects initial data from multiple imm-1-104 phase 2a arms in 2024 - cambridge, mass., april 09, 2024 (globe newswire) -- immuneering corporation (nasdaq: imrx), a clinical-stage oncology company seeking to develop and commercialize universal-ras/raf medicines for broad populations of cancer patients, today presented preclinical data at the american association for cancer research (aacr) annual meeting, which the company views as supportive of its ongoing phase 2a clinical trial of imm-1-104 in ras-mutated advanced or metastatic solid tumors.
2024-04-03 16:05:00 - Press Release
Immuneering To Participate In The 23rd Annual Needham Virtual Healthcare Conference
Cambridge, mass., april 03, 2024 (globe newswire) -- immuneering corporation (nasdaq: imrx), a clinical-stage oncology company seeking to develop and commercialize universal-ras/raf medicines for broad populations of cancer patients, today announced that management will participate in the 23rd annual needham virtual healthcare conference, taking place april 8-11, 2024, to discuss the company's pipeline, platform, and business strategy.
2024-03-27 08:00:00 - Press Release
Immuneering Announces First Patient Dosed In Its Phase 1/2a Trial Of Imm-6-415 To Treat Advanced Solid Tumors With Raf Or Ras Mutations
- deep cyclic inhibitor of the mapk pathway demonstrated strong tumor growth inhibition in preclinical studies of raf or ras mutant tumors, both as monotherapy and in combination - - phase 1 portion of the phase 1/2a trial designed to evaluate the safety, tolerability, pharmacokinetics (pk), and pharmacodynamics (pd) of imm-6-415 and establish a candidate recommended phase 2 dose (rp2d) - -initial pk, pd and safety data expected in 2024 - cambridge, mass., march 27, 2024 (globe newswire) -- immuneering corporation (nasdaq: imrx), a clinical-stage oncology company seeking to develop and commercialize universal-ras/raf medicines for broad populations of cancer patients, today announced that the first patient has been dosed in its phase 1/2a trial of imm-6-415 to treat advanced solid tumors with raf or ras mutations.
2024-03-14 07:00:00 - Press Release
Immuneering Announces Positive Topline Results From Phase 1 Portion Of Its Phase 1/2a Clinical Trial Of Imm-1-104 In Ras-mutant Solid Tumors
- imm-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired ras alterations was observed in evaluable patients profiled for ctdna and treated with imm-1-104, supporting goal of universal-ras activity - - target lesion regression observed in over half of patients treated with imm-1-104 at 320mg or 240mg qd, with best individual lesion regression of -35.7% and best recist sum of longest diameters (sld) of -18.9%, both at 320mg - - candidate rp2d of 320 mg qd supported by tolerability, pk/pd, ctdna results & initial anti-tumor activity - - phase 2a portion of the study underway with three monotherapy and two combination arms in earlier lines of treatment, with initial data from multiple arms expected in 2024 - - immuneering will host an investor call today at 8:30 a...
2024-03-12 08:00:00 - Press Release
Immuneering Appoints Thomas J. Schall, Ph.d.
Cambridge, mass., march 12, 2024 (globe newswire) -- immuneering corporation (nasdaq: imrx), a clinical-stage oncology company seeking to develop and commercialize universal-ras/raf medicines for broad populations of cancer patients, today announced the appointment of thomas j.
Latest News
2024-03-19 02:19:36 - Seeking Alpha
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024.
2024-03-18 12:06:08 - Zacks Investment Research
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
2024-03-05 17:00:00 - GlobeNewsWire
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California.
2024-02-01 08:00:00 - GlobeNewsWire
Immuneering Announces Participation in February Investor Conferences
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferences to discuss the company's pipeline, platform and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
2023-11-20 16:05:00 - GlobeNewsWire
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
2023-10-04 16:05:00 - GlobeNewsWire
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will present preclinical data on IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston.
2023-09-06 08:00:00 - GlobeNewsWire
Immuneering to Present at the Morgan Stanley Healthcare Conference
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Chief Accounting Officer and Treasurer.
2023-07-07 17:55:10 - Seeking Alpha
Immuneering Corp.: Early Stage Promise, But Long-Term Investment
IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going to take time.
2023-07-05 11:32:38 - Zacks Investment Research
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-05-30 08:00:00 - GlobeNewsWire
Immuneering to Present at the Jefferies Healthcare Conference
CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Jefferies Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.